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S U M M A R Y
Objectives: Immune checkpoint pathways regulate optimal host immune responses against transformed
cells, induce immunological memory, and limit tissue pathology. Conversely, aberrant immune
checkpoint activity signiﬁes a poor prognosis in cancer and infectious diseases. Host-directed therapy
(HDT) via immune checkpoint blockade has revolutionized cancer treatment with therapeutic
implications for chronic infections, thus laying the foundation for this review.
Methods: Online literature searches were performed via PubMed, PubMed Central, and Google using the
keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer
immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-speciﬁc
cells”; “tuberculosis”; “malaria”; “viral infections”; “human immunodeﬁciency virus”; “hepatitis B
virus”; “hepatitis C virus”; “cytomegalovirus” and “Epstein–Barr virus”. Search results were ﬁltered based
on relevance to the topics covered in this review.
Results: The use of monoclonal antibodies directed against the antigen-experienced T-cell marker
programmed cell death 1 (PD-1) and its ligand PD-L1 in the context of chronic infectious diseases is
reviewed. The potential pitfalls and precautions, based on clinical experience from treating patients with
cancer with PD-1/PD-L1 pathway inhibitors, are also described.
Conclusions: Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic infectious
diseases such as tuberculosis and HIV, and must therefore be tested in randomized clinical trials.
© 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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versus periphery
The chronicity of cancer and persistent infections provides
constant antigen exposure to antigen-reactive T-cells, leading to
cellular exhaustion and abrogation of effector functions.1 The
expression of cell surface-bound molecules such as programmed
cell death protein 1 (PD-1/CD279) and cytotoxic T lymphocyte-
associated protein 4 (CTLA-4/CD152) on antigen-speciﬁc T-cells are
markers of exposure to immunogenic stimuli.2 PD-1 and CTLA-
4 identify as immune checkpoints due to their crucial role in
regulating the magnitude and quality of T-cell responses. Other
immune checkpoint molecules of clinical relevance are the T-cell
immunoglobulin and mucin-domain containing 3 (TIM-3), with its
nominal ligand galectin 9, and to a lesser extent high-mobility
group Box 1 (HMGB1)3 and the lymphocyte-activation gene 3
(LAG-3), which binds to major histocompatibility complex (MHC)
class II molecules with higher afﬁnity than the CD4 receptor.4
This review focuses on PD-1 and its ligands. PD-1 expression on
T-cells is rapidly induced after antigen exposure, following
engagement between the T-cell receptor (TCR) and its cognate
epitope-loaded MHC molecule in the draining lymph nodes.5 PD-1
RNA is detectable in T-cells as rapidly as 2 h post TCR-speciﬁc
stimulation.6 In addition to TCR-dependence, the presence of
interleukin 2 (IL-2), IL-7, IL-15, vascular endothelial growth factor
(VEGF), IL-6, and transforming growth factor beta (TGF-b) in the
local cytokine milieu in lymph nodes and diseased tissue
additionally contribute to PD-1 up-regulation on T-cells.7–10 PD-
1 interacts with its ligands, namely PD-L1 (B7-H1/CD274) and PD-
L2 (B7-DC/CD273). The PD-1 ligands are expressed on transformed
cells, professional antigen-presenting cells (pAPCs), and epithelial
cells, as well as T-cells.11 This interaction provides signals that
tolerize T-cells to their antigenic targets, disarming their effector
functions.1,7 Type 1 interferons (IFN-a/b) and tumour necrosis
factor alpha (TNF-a) can up-regulate PD-L1 expression on T-cells,
B-cells, natural killer (NK) cells, myeloid cells, and epithelialFigure 1. Factors that induce PD-1, PD-L1, and PD-L2 expression in host cells. Although t
loaded MHC molecule on transformed cells (infected or cancerous cells), a cytokine mili
VEGF, and IL-2 augment the activation of this immune checkpoint pathway. In addition, c
1 expression during chronic disease. TGF-b is another physiologically important cytokin
molecules such as Mycobacterium tuberculosis LAM can activate the PD-1 pathway in T-ce
exposure to IFN-g, type 1 interferons, TNF-a, and GM-CSF  thus indicative of intense inﬂ
NF-kB activation. The anti-inﬂammatory cytokine IL-4 can also trigger PD-L2 ex
lipopolysaccharide; TLR, toll-like receptor; NF-kB, nuclear factor kappa B.cells,5,7 while PD-L2 expression is inducible via interferon gamma
(IFN-g), granulocyte-macrophage colony-stimulating factor (GM-
CSF), and IL-4 signalling.7 Figure 1 is a schematic representation of
the factors driving PD-1 and PD-L1/2 expression by T-cells and
transformed cells, respectively.
A summary of PD-1 expression by various human cell types is
presented in Table 1.88–99 Biologically, PD-1 expression may play a
beneﬁcial role in ameliorating and curbing the development of
autoimmune disease  although this is not true for cancer and
infections.12 PD-1 expression on T-cells identiﬁes immune cells
that speciﬁcally recognize and react to transformed as well as to
pathogen-derived antigens. More recent studies have shown that
PD-1+ tumour-inﬁltrating T-cells (TIL) contain a distinct repertoire
of tumour-reactive CD8 T-cells that express oligoclonal TCRs,
speciﬁc for mutated tumour epitopes, termed neoantigens.13 PD-1
+ CD8 T-cells recognizing the patient’s cancer cells are also found in
peripheral blood mononuclear cells (PBMCs), albeit in signiﬁcantly
lower numbers compared to the tumour microenvironment.13
PBMC-derived neoantigen-speciﬁc CD8 T-cells can also be
expanded ex vivo for cellular therapy.14 These PD-1+ CD8 TILs
co-express additional surface markers associated with activation
and potential tolerance, such as TIM-3, LAG-3, and the cytotoxic
lymphocyte (CTL) activation marker 4-1BB.13
The biological signiﬁcance of PD-1+ T-cells co-expressing other
exhaustion/activation markers needs to be addressed, although
analysis of PD1+ and 4-1BB+ T-cells, also associated with antigen-
speciﬁcity, does not suggest that a distinct pattern of activation/
exhaustion markers leads to a ﬁner resolution of identifying
antigen-speciﬁc immune cells.13 Early results of phase 1 trials
using activation/exhaustion marker-positive T-cells (e.g., 41-BB+
selected immune cells) showed potentiation of complete regres-
sion of the malignant disease (melanoma) in patients (Steven A.
Rosenberg, personal communication). This offers clinical evidence
that exhaustion/activation marker-selected immune cells are
clinically relevant, warranting use for targeted adoptive cellular
therapy (clinical trials identiﬁer: NCT02111863).he major trigger for PD-1 expression on T-cells is TCR engagement with the epitope-
eu consisting of proinﬂammatory mediators such as IFN-g, type 1 interferons, IL-6,
ytokines important for T-cell maintenance, i.e., IL-7 and IL-15, also contribute to PD-
e that induces PD-1 expression and potentiates regulatory T-cell activity. Antigenic
lls via TLR2 signalling. PD-L1/2 expression on transformed host cells is inducible by
ammation. Bacterial LPS can also induce PD-L1 expression, via TLR4 involvement and
pression. Abbreviations: TCR, T-cell receptor; LAM, lipoarabinomannan; LPS,
Table 1
Summary of PD-1, PD-L1, and PD-L2 in a variety of human cell types.
Cell type PD-1 expression level PD-L1 expression level PD-L2 expression level Ref.
Constitutive Cytokine-induced Constitutive Cytokine-induced Constitutive Cytokine-induced
Naive T-cells Nil Yes Nil Yes Nil Yes 5,7,18,31,
Activated T-cells Yes Increased Yes Increased Nil Yes 61,88–99
Exhausted T-cells Yes Increased Yes Increased Nil Yes
Regulatory T-cells Yes Increased Yes Increased Nil Yes
NK cells Nil Yes Nil Yes Nil Yes
Naive B-cells Yes Increased Yes Increased Yes Increased
Plasma cells Yes Increased Yes Increased Yes Increased
Plasmacytoid DCs Nil Nil Yes Increased Yes Increased
Myeloid DCs Nil Yes Yes Increased Yes Increased
Macrophages Nil Yes Yes Increased Yes Increased
Monocytes Nil Yes Yes Increased Nil Yes
Airway and lung epithelia Nil Nil Nil Yes Nil Yes
Liver non-parenchymal cells Nil Yes Yes Increased Yes Increased
Mesenchymal stromal cells Nil Nil Yes Increased Yes Increased
Pancreatic islets Nil Nil Yes Increased Yes Increased
Fibroblasts Nil Nil Yes Increased Yes Increased
HUVEC Nil Nil Nil Yes Yes Increased
PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; PD-L2, programmed cell death 1 ligand 2; NK, natural killer; DC, dendritic cell; HUVEC, Human
umbilical vein endothelial cells.
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immune system in patients with tuberculosis (TB) is exposed to
new Mycobacterium tuberculosis antigens for an extended period.
Elevated PD-1 expression has been reported on CD4 and CD8 T-
cells,15–19 neutrophils,20 NK T-cells,21,22 and regulatory T-cells
(Tregs)23,24 isolated from patients with drug-susceptible as well as
drug-resistant TB. Furthermore, M. tuberculosis infection of PBMCs
can up-regulate PD-1, PD-L1, and PD-L2 expression on T-cells,15,19
NK cells,25 and monocytes19 therein. Individuals with latent TB
infection (LTBI) also have high levels of PD-1-expressing circulat-
ing CD4 T-cells, which can produce IFN-g (mean frequency of
29.0  2.6%), although T-cells negative for PD-1 expression are
twice as likely to respond to antigenic stimulation via IFN-g, IL-2,
and TNF-a production.26 This observation highlights the need to
identify which PD1+ T-cell subset would indicate ‘exhausted’ and
the antigen-experienced T-cells that can be rescued from activa-
tion-induced cell death or ‘anergy’, and PD1+ T-cells that cannot be
reverted to functional immune cells27 for target identiﬁcation in
infectious diseases.
Thus, the identiﬁcation of PD1+ T-cells and their nominal
targets does not reﬂect merely an academic exercise, but rather a
clinical reality to use these T-cells for targeted cellular therapy. The
analysis of T-cells from lung granulomas of M. tuberculosis-infected
cynomolgus macaques, which very closely mimic the dynamics of
human TB, revealed that approximately 8% of all granuloma-
derived CD3 cells (CD4 and CD8 T subsets) were found to express
PD-1.28 The functional impact of these T-cells (exhausted and non-
functional, or exhausted and antigen-experienced deﬁning clini-
cally relevant target epitopes) is, however, yet to be addressed.
CD8 T-cell exhaustion, mediated by PD-1 expression in HIV
infection, is an important cause of weakened immune clearance of
virus-infected host cells.29,30 Increased PD-1+ CD8 T-cell numbers
in PBMCs of patients with HIV infection correlate positively with
impaired immune effector functions, disease progression, and
declining CD4 T-cell counts.29,31 Similar to TB, Tregs from patients
with HIV infection also express high levels of PD-1.32 Mucosal-
associated invariant T-cells (MAITs) highly expressing CD161 have
also been shown to up-regulate their surface expression of PD-1
protein in HIV-positive as well as HIV–TB co-infected patients; this
is reversible with antiretroviral therapy.33
Effector memory CD8 T-cells isolated from Kenyan children
with persistent exposure to Plasmodium falciparum were also
found to strongly express PD-1 on their surface.34 Although PD-1expression on CD8 T-cells is implicated in the chronicity of
malaria,35 PD-1 expression on T follicular helper cells (TFH) seems
to correlate with protection in children.36 TFH cells are a subset of
antigen-experienced (thus, antigen-speciﬁc) CD4 T-cells resident
in the B-cell follicle of germinal centres within secondary
lymphoid organs such as the tonsils and spleen, and play an
important role in promoting B-cell activation and antibody
production.37 Another important attribute of TFH cells is their
ability to abundantly produce IL-21 (important for T-cell differen-
tiation) and CXCL13, an important B-cell chemoattractant.37 As
such, the functionality of TFH cells can activate antigen-speciﬁc
effector T-cell responses while priming B-cells to strengthen
pathogen-directed humoral immune responses.
In patients with chronic hepatitis B virus (HBV) infection, PD-1+
CD8 T-cells have been found to be impaired in their antiviral
effector functions, and these cells are likely to be targeted for
apoptotic depletion in vivo38,39 – a scenario also true for NK T-cells
in TB.17,22 High levels of PD-1+ CD4 and CD8 T-cells have been
observed among liver-inﬁltrating T-cells in tissue biopsies as well
as explants from patients with hepatitis C virus (HCV) infection.40
Cytomegalovirus (CMV) viraemia in renal transplant recipients
also appears to up-regulate PD-1 expression on CD4 T-cells.41 PD-1
+ CD8 T-cells with antigen-speciﬁc TCRs may also reside in the
bone marrow. IFN-g-producing T-cells derived from bone marrow
of patients with pancreatic cancer have been reported to exhibit
pronounced reactivity to pancreatic tumour cell lysate in an MHC-
I-dependent manner.42 PD-1+ CD8 TILs have been found in brain
metastases in patients with renal cell carcinoma,43 while increased
numbers of HIV-speciﬁc PD-1+ CD8 T-cells in cerebrospinal ﬂuid
have been reported for patients with HIV infection.44
The expression of PD-1 on T-cells circulating in PBMCs is
gaining momentum as a marker of disease progression. In patients
with non-small cell lung cancer (NSCLC), a dramatic decrease in
circulation of CD8 T-cells expressing PD-1 appeared to be
concomitant with overall survival after vaccination with a peptide
vaccine candidate.45 In contrast, an increase in circulating PD-1+
CD4 T-cells also correlated with overall survival, suggesting a
greater degree of epitope spreading recognized by CD4 T-cells.
Circulating CD8 T-cells from patients with RCC who underwent
surgical resection displayed a higher degree of activation,
concomitant with reduced PD-1 expression and increased
CD69 expression on the cell surface.46 The prognostic value of
PD-1 expression on immune cells may also apply to malaria,34,47
224 M. Rao et al. / International Journal of Infectious Diseases 56 (2017) 221–228TB,17,20,22 and chronic viral infections.29,39,48 These studies indicate
that the dynamics of T-cell populations in peripheral blood of
patients with cancer and infectious disease are, to some extent,
representative of the changes occurring in the microenvironment
of affected tissues.
PD-1:PD-L1 blockade as host-directed therapy
Cancer
Immune checkpoint blockade using monoclonal antibodies
(mAbs) now constitutes an integral component of host-directed
therapy (HDT). HDTs exploit aberrant host biological pathways
that can be corrected by interfering with the respective ligands.
The most clinically successful HDT has been the immunological
blockade of PD-1 in cancer. The United States Food and Drug
Administration (FDA)-approved anti-PD-1 mAbs, e.g. nivolumab
and pembrolizumab, successfully disrupt contact with PD-L1/2 to
reverse T-cell exhaustion (CD8 and CD4) and restore their anti-
tumour potential, combining minimal off-target toxicity with high
efﬁcacy (Figure 2).49 The induction of this speciﬁc tumouricidal
activity by anti-PD-1 therapy correlates with increased propor-
tions of neoantigen-speciﬁc CD8 TCRs in the peripheral blood of
patients.50 Thus, anti-PD-1 therapy is able to mobilize and to
activate a subpopulation of specialized CD8 TILs to improve patient
survival.
Tregs express exceptionally high levels of PD-1 on their surface;
this is necessary for the maintenance of immunological balance to
avoid overt inﬂammation and tissue destruction.5 By targeting PD-
1, Treg populations are as likely to be blocked from dampening
host-protective effector T-cell responses, in addition to the directFigure 2. Blockade of the PD-1/PD-L1/2 pathway potentiates productive immune respo
mediated signalling pathway (initiated upon interaction between PD-1 and PD-L1/2) usin
cancer. The same is envisaged for pathogen-speciﬁc T-cells in infectious diseases  as 
unleashes their ability to produce proinﬂammatory cytokines, i.e., IFN-g and TNF-a, as w
lyse and kill transformed cells in the host to control the spread and burden of diseaseeffect on the latter. PD-1 blockade with pembrolizumab has also
shown superiority over monotherapy with ipilimumab (anti-
CTLA4) in patients with advanced melanoma.51In a prospective
study, 23 of 53 advanced patients with melanoma treated with a
combination of ipilimumab and nivolumab displayed an objective
response, some with over 80% tumour regression.52 Thus,
compared to CTLA-4, PD-1 appears to a have a greater impact
on establishing T-cell tolerance due to the magnitude of the clinical
effect of its blockade.
At least two other anti-PD-1 mAbs (PDR001 and REGN2810) are
in clinical trials for advanced cancers. The combinatorial effect of
anti-CTLA4 and anti-PD-1 treatment imparts an additive effect of a
two-pronged tumour reduction, should patients not respond to
anti-CTLA-4 monotherapy. For patients with tumours expressing
more PD-L1 and PD-L2 molecules than B7.1 (CD80) and B7.2
(CD86), the ligands for CTLA-4 may not respond as effectively to
anti-CTLA-4 therapy. The same is true for the number of PD-1+ and
CTLA-4+ tumour-speciﬁc TILs and circulating T-cells in the patient.
A useful selection criterion prior to initiation of anti-PD-1 therapy
would be to perform cellular analysis of the proportion of T-cells
and tumour cells expressing PD-1/PD-L1/2 as opposed to CTLA-4/
B7.1/2 in the tumour biopsy (microenvironment) as well as PBMCs
of the patient. Several biopsies from the same patient, to account
for tumour heterogeneity in the same individual, will further
facilitate clinical decision-making to initiate combination therapy
with immune checkpoint inhibitors.
To the best of the authors’ knowledge, four monoclonal
antibodies targeting PD-L1 have entered clinical trials for cancer.53
The ﬁrst of these to be tested was BMS-936559; treatment resulted
in disease stabilization up to 24 weeks in patients with metastatic
melanoma (27%), NSCLC (12%), ovarian cancer (18%), and RCCnses in cancer and infectious diseases. Immune checkpoint inhibition of the PD-1-
g monoclonal antibodies leads to activation of exhausted antigen-speciﬁc T-cells in
seen in TB and chronic viral infections. Activation of these antigen-speciﬁc T-cells
ell as cytolytic molecules such as perforin, granzyme B, and granulysin  which can
.
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MPDL3280A treatment,55,56 while trials for two other anti-PD-L1
antibodies, namely MEDI4736 and MSB0010718C, are underway.
Relying on a single therapeutic agent to obtain long-term and
stable disease remission may not be viable. Topalian et al. recently
published the long-term survival of patients with metastatic
melanoma who received nivolumab at different doses: the mean
overall survival reported was a little over 2 years (approximately
25 months).57 Given that anti-PD-1 therapy mobilizes the
repertoire of neoantigen-speciﬁc TILs into circulation,50 adoptive
T-cell therapy covering the epitopes recognized by the patient’s
immune system would serve as an excellent adjunct to chemo-
therapy, as well as immune checkpoint inhibition.58 The same
applies to the chronic infectious diseases such as TB, HIV, hepatitis,
and malaria discussed in this review.
Infectious diseases
The phenomenon of T-cell exhaustion in chronic infections and
its similarity to cancer has been reviewed elsewhere.1 In light of its
success in cancer therapy, anti-PD-1/PD-L1 therapy has adequate
precedent to be trialled in the treatment of severe chronic
infectious diseases. Immune checkpoint inhibition in infectious
disease therapy may be administered adjunctively to standard
drug treatment  akin to cancer chemotherapy.
Exaggerated proinﬂammatory cytokine responses and subopti-
mal antigen-speciﬁc T-cell activity are equally responsible for
severe tissue damage in human TB and poor clearance of M.
tuberculosis infection.21,22,26,59 There is some evidence in the
literature to support the potential beneﬁt of anti-PD-1 therapy in
TB. In vitro blockade of PD-1 with monoclonal antibodies has been
shown to restore TB antigen responsiveness, cytokine secretion,
and proliferation and cytolytic activity of circulating T-cells and NK
cells from TB patients. More recently, anti-TB therapy was reported
to promote reduced expression of PD-1 and its ligands,18,60 as well
as increased expression of the anti-apoptotic protein B-cell
lymphoma 2 in T-cells.17 The same has been observed for PD-
L1 expressed on neutrophils. Using anti-PD-1 therapy in adjunct to
standard anti-TB treatment may, therefore, potentiate a two-
pronged (antibiotics and T-cell-driven) antimycobacterial effect,
offering an overall clinical beneﬁt to patients.
Preclinical evaluation of anti-PD-1 therapy for HIV infection has
been evaluated using the non-human primate model of simian
immunodeﬁciency virus infection.61 PD-1 blockade reversed T-cell
exhaustion while reducing viral load as well as various opportu-
nistic infections in non-human primates. More recently, ex vivo
blockade of PD-L1 on PB Tregs from HIV-positive individuals
independent of viraemia was shown to trigger expansion and
potentiate effector functions of virus-speciﬁc CD8 T-cells.32 In
addition to this effect, the proliferative capacity of Tregs, although
increased by PD-L1 inhibition, did not inﬂuence the ability of the
cells to induce immunosuppression. PD-1 blockade appears to
augment reduced hyper-activation of type 1 IFN responses, which
in part translates to a lower incidence of systemic cytokine storms
and immune dysregulation in HIV infection,61 which can reduce
tissue pathology in patients. In pulmonary TB, an exaggerated type
1 interferon response in the lung markedly promotes M.
tuberculosis replication and extensive tissue destruction.62 Accord-
ingly, pre-antiretroviral therapy IFN-a levels were shown to be up-
regulated by at least 10-fold in HIV–TB patients who went on to
develop immune reconstitution inﬂammatory syndrome (IRIS), as
well as those who died within 6 months of antiretroviral therapy
initiation.63
In chronic human HBV infection, in vitro blockade of PD-L1 on
CD8 and CD4 T-cells from PB and liver biopsies of patients resulted
in enhanced IFN-g and IL-2 production.64 Patients with chronicHCV infection treated with nivolumab were reported to respond
well, some achieving more than a 4-log reduction in viral load after
treatment.65 The analysis of sera from healthy individuals as well
as haematopoietic stem cell transplantation (HSCT) recipients with
transient or persistent CMV infection revealed that the latter group
had the highest amount of IL-6 produced by CD33 + PD-L1+
adherent cells, which in turn induced PD-1 expression on virus-
speciﬁc CD8 T-cells.10 In vitro blockade of PD-L1 in PBMCs isolated
from these patients led to signiﬁcant expansion of tetramer-
positive virus-speciﬁc CD8 T-cells, indicating that PD-L1 blockade
may be clinically favourable in managing chronic CMV disease.10
Blockade of PD-L1 in a murine model of cerebral malaria
exacerbated inﬂammation and haemorrhage in the brain com-
pared to untreated controls.66 However, blocking PD-1 as well as
LAG-3 in the blood stage of murine malaria (which resembles the
erythrocyte stage in human malaria) proved beneﬁcial, manifest-
ing in dramatic parasitaemia reduction and improved antibody as
well as CD4 (also TFH) and CD8 T-cell responses, associated with
elimination of chronic infection as well as extended survival.67
Anti-PD-1:PD-L1/2 therapy: improved efﬁcacy with acceptable
toxicity
Generally mild to moderate immune-related adverse effects
(irAEs) have been reported in patients with anti-PD-1:PD-L1
therapy.68 Three out of 296 patients with advanced solid tumours
(two patients with NSCLC, one patient with CRC (colorectal
cancer)) who received nivolumab treatment in the ﬁrst anti-PD-
1 clinical study were reported to have died due to treatment-
induced pneumonitis (inﬂammation of the alveolar wall, grade 3 or
4 irAE), nevertheless accounting for only 1% of total mortality (21%)
in the cohort.69 A clinical trial of nivolumab therapy in patients
with advanced NSCLC (n = 129) also reported three deaths (2% of
patients) due to treatment-induced pneumonitis, although objec-
tive responses were seen in 22 patients (17%).70 A more recent
phase 2 evaluation of nivolumab in patients with metastatic RCC
reported that only eight patients who received treatment
subsequently developed pneumonitis, with no treatment-related
deaths occurring over the duration of the trial.71 Thus, the fatality
rate due to anti-PD-1:PD-L1 therapy is signiﬁcantly low compared
to the clinical beneﬁts gained by the patients with advanced cancer
undergoing immune checkpoint inhibition treatment.
Sporadic cases of the development of anti-PD-1 therapy-
associated type 1 diabetes mellitus (autoimmune insulin-depen-
dent diabetes mellitus, T1DM) in patients have also been
reported.72,73 In general, high titres of autoantibodies against
glutamate decarboxylase (GAD), and in some patients with an
HLA-A2+ background, CD8 T-cells recognizing epitopes from
insulin alpha and beta chains, preproinsulin, GAD65, and islet-
speciﬁc glucose-6-phosphatase catalytic subunit-related protein
(IGRP) (0.2% to 2% tetramer-speciﬁc cells of total PBMCs) were
detected in peripheral blood. Autoimmune myocarditis, concomi-
tant with increased CD8 T-cells and reduced Tregs (in a myocardial
biopsy) has been reported in one patient with metastatic
melanoma who received pembrolizumab.74 These case reports
contribute to a better understanding of irAEs that may be valuable
for the clinical immune-monitoring of patients undergoing anti-
PD-1:PD-L1 therapy, rather than to discourage their use altogether.
Essentially, the adverse effects reported for patients with
metastatic cancer receiving anti PD-1 therapy may be far less
harmful than the off-target toxicities of standard chemotherapy,
which also impairs the patient’s quality of life.53,75 In addition, the
inﬂammatory side effects associated with anti-PD-1:PD-L1 thera-
py, i.e., pneumonitis and gastrointestinal inﬂammation, are
clinically manageable with immunosuppressive corticoste-
roids.53,69,70 Weber et al. reported 38% objective responses in
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(n = 268) versus a meagre 5% of patients who underwent the
investigators’ choice of chemotherapy or ICC (n = 102).76 Further-
more, more patients who were treated with ICC (32 patients, 32%)
exhibited grade 3 or 4 AEs as compared to patients treated with
nivolumab (24 patients, 9%). In a more recent retrospective report
of a European multicenter clinical trial assessing the efﬁcacy and
safety of nivolumab or pembrolizumab therapy for advanced
melanoma, 138 of 496 treated patients exhibited grade 1 or 2 irAEs,
conditions that are either treatable with steroids or even
negligible.68 Thus, the proven clinical efﬁcacy of anti-PD-1:PD-
L1 therapy against melanoma and other solids tumours compen-
sates for acceptable and manageable side effects observed in a
small fraction of patients.
Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for
combination with other immunotherapies
Due to its robustness, blocking PD-1 delivers the probable risk
of activating subpopulations of autoreactive and pathogenic T-cell
subsets in the patient, as seen with the onset of inﬂammatory
conditions in individuals receiving anti-PD-1 therapy without a
previous history of the disease. In contrast, blockade of PD-L1 alone
would elicit less prominent T-cell responses compared to blocking
PD-1, since it can still interact with PD-L2, although expression of
the latter is more restricted than PD-L1.5 This, however, comes
with the advantage of reduced toxicity.77 Nevertheless, the relative
efﬁcacy and toxicity of anti-PD-1 and anti-PD-L1 agents at present
appear to be quite similar, and further work is necessary to
delineate the potential differences in efﬁcacy and toxicities of
these agents.
In addition to using monoclonal antibodies targeting the PD-1/
PD-L1 pathway, cytokine therapy, antibodies targeting cytokines
and other cell-surface markers, as well as cellular therapy are
potentially powerful interventional tools. Given that the local and
systemic cytokine milieu in patients with chronic infection and
cancer contributes to T-cell exhaustion and tolerance, timely
delivery of cytokines that can reverse exhaustion could augment
the therapeutic activity of anti-PD-1/PD-L1 antibodies. Alterna-
tively, antibodies that neutralize TNF-a, IL-6, TGF-b, and/or VEGF
in combination with anti-PD-1/PD-L1 antibodies could be as
clinically beneﬁcial, in terms of reducing unwanted and destruc-
tive inﬂammation. Using the example of 3/15 patients with
advanced melanoma who had disease progression after at least 6
months of remission, Zaretsky et al. recently reported that the
outgrowth of metastatic tumours with mutations in the Janus
kinase 1 or 2 genes (JAK1 or 2), which disrupts IFN-g-induced cell
growth arrest as well as mutations in the b2-microglobulin gene
(which is involved in MHC-1 antigen presentation), might promote
late acquired resistance to anti-PD-1 therapy.78 JAK1 mutations
could, therefore, serve as a biomarker for the efﬁcacy of anti-PD-1:
PD-L1 therapy, and could be tested for prior to initiating treatment.
Another interesting host target is CD70, a surface receptor
expressed on lymphocytes and myeloid cells associated with T-cell
activation and memory formation, albeit with a poor prognosis in
cancer and infection.79–82 CD70 expression inhibits the function-
ality of effector memory TILs in RCC and melanoma,79,80 while
viraemic and lymphopenic HIV-infected individuals have high
frequencies of CD70-expressing PB CD4 T-cells.81 Anti-
CD70 treatment has been shown to reduce Treg proliferation,
activate TILs, potentiate antibody-mediated cellular cytotoxicity to
kill human tumour cells, and also to extend the survival of Burkitt’s
lymphoma-bearing mice.83 There are at least two anti-CD70 mAbs
in clinical trials for RCC and non-Hodgkin’s lymphoma at present
(ARGX-110 and MDX-1203).The clinical effect of anti-PD-1/PD-L1 therapy is very pro-
nounced in tumour-reactive TILs since PD-1 expression is
signiﬁcantly higher on TILs than circulating T-cells from cancer
patients.13 It has also been learned that most anti-cancer T-cell
responses potentiated by PD-1 therapy target mutated epitopes.50
This may also resonate in infectious diseases, especially those
perpetrated by drug-resistant pathogens. While subdued CD8 T-
cell responses to viral escape neoantigens has been shown to
facilitate viral persistence and disease progression in the host,84,85
host-protective T-cell responses to M. tuberculosis mutated
antigens is not known but warrants formal testing using clinical
material from patients with drug-sensitive and drug-resistant
TB.86,87
Conclusions
The therapeutic efﬁcacy of monoclonal antibodies against PD-1
and PD-L1 in patients with cancer prompts extensive clinical
evaluation in patients with chronic infectious diseases, especially
in light of increasing drug resistance. Regardless of the short-
comings reported in patients receiving anti-PD-1/PD-L1 therapy,
the proven clinical success of blocking this immune checkpoint
pathway certainly encourages its further use  particularly if
clinically meaningful inclusion criteria and markers of responses
can be identiﬁed (thus, precision medicine). Taking TB as a
paradigm, the high expression of PD-1 in patients with drug-
refractory disease as well as those with HIV-related IRIS is
targetable for anti-PD-1 therapy. Clinical studies involving
metastatic melanoma patients have revealed that doses up to
3 mg/kg are well tolerated by patients (in terms of acceptable
irAEs), and produce highly encouraging treatment out-
comes.52,68,69 Designing clinical trials to test the efﬁcacy of PD-l
blockade in TB should therefore consider involving patients with
extensive chest radiographic ﬁndings and blood inﬂammatory
markers (including cytokines such as IL-6, IFN-g, TNF-a, IFN-a/b
etc.), as well as poor responsiveness to drug therapy. Patients with
multidrug-resistant or extensively drug-resistant (MDR/XDR) TB
would represent an excellent cohort for intervention. The
adjunctive administration of anti-PD-1 antibodies to TB patients
undergoing anti-TB drug therapy  for drug-susceptible or drug-
resistant TB disease  could potentially eradicate M. tuberculosis
reservoirs in organs inaccessible to chemotherapeutic agents but
not immune cells. Anti-PD-1 treatment, after the intensive phase of
anti-TB therapy, may activate anergic and exhausted M. tuberculo-
sis-speciﬁc T-cells in the patient. In addition to offering an
improved point-of-care intervention for otherwise helpless
patients, immune checkpoint inhibition has also shed new light
on the pathobiology of disease. This opens up new and exciting
avenues of basic and clinical research that may materialize in
hitherto unknown therapeutic strategies. Borrowing this knowl-
edge should lead to revised regimens of combination therapy
incorporating immune checkpoint inhibitors and antibiotics, as
well as repurposed drugs for the effective management of chronic
diseases.
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